Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Andecaliximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RA POC
- Sponsors Gilead Sciences
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.